Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Oncor disappears from the Amex:

This article was originally published in Clinica

Executive Summary

Oncor, the troubled gene-based diagnostic company, has had its shares suspended indefinitely from the American Stock Exchange (AMEX). AMEX had already applied to the Securities and Exchange Commission to remove Oncor from the market - a move that Oncor had opposed. Now, Oncor's failing liquidity (see Clinica No 828, p 9) has prompted the delisting. It is not known whether the Gaithersburg, Maryland, company will attempt to get a quote on one of the alternative markets.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts